Table 3.
Cost-effectiveness results
| Outcome | ΔC (95% CI)a | ΔE (95% CI) | ICER | CE plane | |||
|---|---|---|---|---|---|---|---|
| Main analysis | NE | SE | SW | NW | |||
| EORTC QLQ-C30 summary score | − 2759 (− 4855; − 557)c | 1.33 (− 0.049; 3.15)b | − 2073 | 1% | 92% | 7% | 0% |
| QALYs | − 2759 (− 4855; − 557)c | − 0.021 (− 0.083; 0.040)c | 129,164 | 0% | 24% | 75% | 1% |
| Complete case analysis (SA1) | |||||||
| EORTC QLQ-C30 summary score | − 4046 (− 8893; − 52)c | 2.21 (0.71; 3.62)b | − 1832 | 3% | 97% | 0% | 0% |
| QALYs | − 4046 (− 8893; − 52)c | − 0.023 (− 0.099; 0.056)c | 178,551 | 2% | 26% | 71% | 1% |
| Healthcare perspective (SA2) | |||||||
| EORTC QLQ-C30 summary score | 199 (− 1115; 1643)c | 1.75 (− 0.044; 3.54)b | 114 | 60% | 38% | 0% | 2% |
| QALYs | 199 (− 1115; 1643)c | − 0.021 (− 0.083; 0.040)c | − 9296 | 10% | 14% | 24% | 52% |
| Undiscounted analysis (SA3) | |||||||
| EORTC QLQ-C30 summary score | − 2816 (− 4996; − 564)c | 1.75 (− 0.044; 3.54)b | − 1612 | 1% | 96% | 3% | 0% |
| QALYs | − 2816 (− 4996; − 564)c | − 0.021 (− 0.084; 0.041)c | 131,134 | 0% | 24% | 75% | 1% |
| Unadjusted analysis (SA4) | |||||||
| EORTC QLQ-C30 summary score | − 3895 (− 6060; − 1693)c | 1.75 (− 0.044; 3.54)b | − 2230 | 0% | 97% | 3% | 0% |
| QALYs | − 3895 (− 6060; − 1693)c | 0.023 (− 0.048; 0.094) | − 167,574 | 0% | 74% | 26% | 0% |
| Per protocol analysis (SA5) | |||||||
| EORTC QLQ-C30 summary score | − 2279 (− 4786; 313)c | 2.33 (0.35; 4.30)b | − 979 | 5% | 94% | 1% | 0% |
| QALYs | − 2279 (− 4786; 313)c | − 0.013 (− 0.079; 0.052)c | 169,659 | 1% | 33% | 62% | 4% |
| Subgroup tumour stage 1 (SA6) | |||||||
| EORTC QLQ-C30 summary score | − 3296 (− 7037; 243)c | 0.85 (− 2.23; 3.93)b | − 3892 | 3% | 68% | 28% | 1% |
| QALYs | − 3296 (− 7037; 243)c | 0.051 (− 0.052; 0.15)c | − 65,267 | 3% | 81% | 15% | 1% |
| Subgroup tumour stages 2 and 3 (SA7) | |||||||
| EORTC QLQ-C30 summary score | − 2275 (− 5221; 362) | 2.24 (0.028; 4.45)b | − 1016 | 6% | 92% | 2% | 0% |
| QALYs | − 2275 (− 5221; 362) | − 0.064 (− 0.14; 0.0095)c | 35,652 | 0% | 4% | 90% | 6% |
95% CI 95% confidence interval, CE plane cost-effectiveness plane, ICER incremental cost-effectiveness ratio, NE north-east quadrant, NW north-west quadrant, SE south-east quadrant, SW south-west quadrant, QALY quality-adjusted life year, EORTC QLQ-C30 European organization for research and treatment for cancer quality of life questionnaire
aUncertainty around cost differences estimated using the non-parametric bootstrap with 5000 replications (bias-corrected intervals). The presented cost differences are unadjusted
bThe difference in EORTC QLQ-C30 summary score represent an overall effect time (36 months), which means that a correction for repeated observations took place
cThe regression model for costs was adjusted for utility and EORTC score at baseline. The regression model for QALYs was adjusted for baseline utility